



Survey of 50 General Medical Oncologists: Urothelial Bladder Cancer (UBC)


Topics of Interest for Future CME Programs



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to early data with EV for nonmetastatic UBC?




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the current role of EV/pembrolizumab as front-line therapy for mUBC?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the optimal sequencing of available therapeutic options for second- and later-line treatment of relapsed/refractory mUBC?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the implications for the management of mUBC of the recent FDA approval of trastuzumab deruxtecan for pretreated HER2-positive solid tumors?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the available clinical data with and potential clinical role of disitamab vedotin for previously treated HER2-positive and HER2-low or negative mUBC?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the comparative tolerability profiles of approved and investigational antibody-drug conjugates for mUBC?




Well informed


Uninformed

Survey of 50 General Medical Oncologists: Prostate Cancer

Topics of Interest for Future CME Programs




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the optimal application of enzalutamide with and without ADT in clinical practice for nonmetastatic HSPC?




Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the current role and selection of treatment intensification approaches for metastatic HSPC?



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to key efficacy and safety outcomes from Phase III trials evaluating PARP inhibitors combined with androgen pathway inhibitors for mCRPC?



How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to individualizing the selection of olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide for patients with mCRPC?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the incidence and spectrum of cardiovascular adverse events and other notable side effects with secondary hormonal agents for prostate cancer?




Well informed


Uninformed

Survey of 50 General Medical Oncologists: Renal Cell Carcinoma (RCC)

Topics of Interest for Future CME Programs




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the appropriate integration of adjuvant pembrolizumab for localized RCC?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the optimal selection of patients with treatment-naïve advanced RCC for treatment with nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the major outcomes from the COSMIC-313 trial and the potential clinical role of nivolumab/ipilimumab in combination with cabozantinib for patients with intermediate- or poor-risk advanced RCC?




Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the rational sequencing of available therapies for RCC progressing on front-line immune checkpoint inhibitor-based regimens?




How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to integrating subcutaneous nivolumab into the current treatment algorithm for previously treated RCC?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the role of HIF-2 α inhibitors for sporadic and VHL-associated RCC?



Well informed

Uninformed


How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to current and emerging treatment options for non-clear cell RCC?



Well informed

Uninformed

How comfortable and/or familiar are you with the published datasets, available guidelines, investigator perspectives and ongoing research pertaining to the recent label update for lenvatinib and the implications for the current clinical management of previously untreated non-clear cell RCC?



Well informed

Uninformed